Xinjing Zhiyuan Biotechnology Files for IPO Following Investment from Tencent and Other Investors

Tianyancha App shows that recently, Neowise Biotechnology (Suzhou) Co., Ltd. underwent industrial and commercial changes, adding Guangxi Tencent Venture Investment Co., Ltd., Wenzhou Tonggao Chuangyue Venture Investment Partnership (Limited Partnership), etc., as shareholders. Meanwhile, the registered capital increased from approximately 6.2807 million RMB to about 7.7922 million RMB.

Neowise Biotechnology, Co., Ltd. was established in September 2020, with Peng Songming as the legal representative. Its business scope includes pharmaceutical production, medical research, and experimental development, among others. The company is currently jointly held by Peng Songming, Guangzhou Baidu Ventures Artificial Intelligence Equity Investment Partnership (Limited Partnership), and the aforementioned new shareholders. According to its official website, the company is an innovative enterprise focused on developing TCR-T immunocyte therapeutic drugs for solid tumors, as well as researching clinical technologies and their translation.